Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GSK690693 + OSU-T315 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GSK690693 | GSK-690693 | AKT Inhibitor (Pan) - ATP competitive 7 | GSK690693 is a ATP-competitive pan-AKT inhibitor, which inhibits AKT signaling, resulting in decreased proliferation and increased apoptosis of tumor cells (PMID: 18381444, PMID: 31377021). | |
OSU-T315 | OSUT315|OSU T315 | OSU-T315 is an ILK inhibitor potentially inhibiting Akt signaling and inducing tumor cell cytotoxicity (PMID: 32439931, PMID: 25293770). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA E545K | breast cancer | sensitive | GSK690693 + OSU-T315 | Preclinical - Cell culture | Actionable | In a preclinical study, OSU-T315 and GSK690693 combination treatment increased cell death compared to GSK690693 alone in a breast cancer cell line harboring PIK3CA E545K in culture (PMID: 32439931). | 32439931 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|